Bristol-myers Squibb Compnay

Bristol-myers Squibb Holdings Ireland

Jason T Goodrich

David R Langley

Nicholas A Meanwell

Lawrence B Snyder

Omar D Lopez

Jeffrey Lee Romine

Denis R St Laurent

Fukang Yang

Andrew Charles Good

Makonen Belema

Van N Nguyen

Lawrence G Hamann

Edward H Ruediger

Alain Martel

Carol Bachand

Daniel H Deon

Clint A James

Rico Lavoie

Gan Wang

Paul Michael Scola

Kevin W Gillman

Michael A Poss

Claudio Mapelli

Kenneth M Boy

Michael H Serrano-Wu

Yuping Qiu

Ramesh Kakarla

Xuejie Yang

Dane M Springer

B Narasimhulu Naidu

Li-Qiang Sun

Alicia Regueiro-Ren

Joanne J Bronson

Eric P Gillis

Thomas W Hudyma

Yasutsugu Ueda

Qian Zhao

Yunhui Zhang

Xiaofan Zheng

Eric Mull

John D Matiskella

Margaret E Sorenson

Timothy P Connolly

Oak K Kim

Guo Li

Zhaoxing Meng

Jayne Kapur

M Nicholas Meanwell

Belema Makonen

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Immunomodulators acting as antagonists of PD-1

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

Growing community of inventors

Meriden, CT, United States of America

Jason T Goodrich